LivaNova (LIVN) Capital Expenditures Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -6.72% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 15.89% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -47.73% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -11.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -43.42% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 27.22% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | 32.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.44% |
| Dec 31, 2025 | 209.75% |
| Sep 30, 2025 | 26.08% |
| Jun 30, 2025 | 24.61% |
| Mar 31, 2025 | 68.65% |
| Dec 31, 2024 | -19.45% |
| Sep 30, 2024 | 108.16% |
| Jun 30, 2024 | 114.81% |
| Mar 31, 2024 | -16.75% |
| Dec 31, 2023 | 41.44% |
| Sep 30, 2023 | 44.31% |
| Jun 30, 2023 | -7.64% |
| Mar 31, 2023 | 47.36% |
| Dec 31, 2022 | 20.42% |
| Sep 30, 2022 | 84.68% |
| Jun 30, 2022 | -4.30% |
| Mar 31, 2022 | -36.56% |
| Dec 31, 2021 | 15.29% |
| Sep 30, 2021 | -68.82% |
| Jun 30, 2021 | -31.59% |
| Mar 31, 2021 | -4.39% |
| Dec 31, 2020 | -16.62% |
| Sep 30, 2020 | 74.69% |
| Jun 30, 2020 | 85.12% |
| Mar 31, 2020 | 49.75% |
| Dec 31, 2019 | -38.69% |
| Sep 30, 2019 | -49.25% |
| Jun 30, 2019 | -23.87% |
| Mar 31, 2019 | -1.80% |
| Dec 31, 2018 | 44.14% |
| Sep 30, 2018 | 30.29% |
| Jun 30, 2018 | -9.75% |
| Mar 31, 2018 | -22.73% |
| Dec 31, 2017 | -5.35% |
| Sep 30, 2017 | -26.00% |
| Mar 31, 2017 | -7.02% |